Accelerate Diagnostics In... (AXDX)
Company Description
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East.
The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.
The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012.
Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Country | United States |
IPO Date | Apr 7, 1994 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 107 |
CEO | Jack Phillips |
Contact Details
Address: 3950 South Country Club Road Tucson, Arizona United States | |
Website | https://acceleratediagnostics.com |
Stock Details
Ticker Symbol | AXDX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000727207 |
CUSIP Number | 00430H102 |
ISIN Number | US00430H2013 |
Employer ID | 84-1072256 |
SIC Code | 3826 |
Key Executives
Name | Position |
---|---|
Jack Phillips | Chief Executive Officer, President & Director |
David Patience | Chief Financial Officer |
Lawrence Michael Mertz | Chief Technology Officer |
Chris Thode | Senior Vice President of US Commercial |
John Meduri | Chief Strategy Officer |
Laura Pierson | Investor Relations Officer |
Maya Gowri | Senior Vice President & Head of Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 21, 2025 | 8-K | Current Report |
Mar 21, 2025 | 8-K | Current Report |
Mar 21, 2025 | 10-K | Annual Report |
Feb 27, 2025 | 4 | Filing |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 06, 2025 | SCHEDULE 13D/A | [Amend] Filing |
Feb 04, 2025 | 4 | Filing |
Jan 30, 2025 | 8-K | Current Report |
Jan 10, 2025 | 8-K | Current Report |
Jan 07, 2025 | SCHEDULE 13G/A | [Amend] Filing |